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disease and hepatocellular carcinoma worldwide. Furthermore,
HCV-induced liver disease is a major indication of liver transplan-
tation. In the past years, direct-acting antivirals (DAAs) targeting
HCV enzymes have been developed. DAAs increase the virologic
response to anti-HCV therapy but may lead to selection of
drug-resistant variants and treatment failure. To date, strategies
to prevent HCV infection are still lacking and antiviral therapy
in immunocompromised patients, patients with advanced liver
disease and HIV/HCV-co-infection remains limited. Alternative
or complementary approaches addressing the limitations of cur-
rent antiviral therapies are to boost the host’s innate immunity or
interfere with host factors required for pathogenesis. Host-target-
ing agents (HTAs) provide an interesting perspective for novel
antiviral strategies against viral hepatitis since they have (i) a
high genetic barrier to resistance, (ii) a pan-genotypic antiviral
activity, and (iii) complementary mechanisms of action to DAAs
and might therefore act in a synergistic manner with current
standard of care or DAAs in clinical development. This review
highlights HTAs against HCV infection that have potential as
novel antivirals and are in preclinical or clinical development.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
With approximately 130 million chronically infected individuals
worldwide, hepatitis C virus (HCV) infection is a major cause of
chronic liver disease including liver cirrhosis, liver failure and
hepatocellular carcinoma (HCC) [1–3]. HCV-induced liver cirrho-
sis and HCC are major indications for liver transplantation (LT)Journal of Hepatology 20
Keywords: Hepatitis C virus; Antivirals; Host-targeting agents.
Received 27 July 2012; received in revised form 26 September 2012; accepted 27
September 2012
⇑ Corresponding authors. Address: Inserm U748, Université de Strasbourg, 3 Rue
Koeberlé, F-67000 Strasbourg, France. Tel.: +33 3 68 85 37 03; fax: +33 3 68 85 37
24.
E-mail addresses: Mirjam.Zeisel@unistra.fr (M.B. Zeisel), Thomas.Baumert@
unistra.fr (T.F. Baumert).
Abbreviations: DAA, direct-acting antiviral; HBV, hepatitis B virus; HCV, hepatitis
C virus; HIV, human immunodeﬁciency virus; HTA, host-targeting agent; IFN,
interferon; miR, microRNA; RBV, ribavirin.lic health [5].
HCV is a single-stranded RNA virus of positive polarity belong-
ing to the Flaviviridae family and the hepacivirus genus (reviewed
in [6]). While six major genotypes and several different subtypes
have been described worldwide, the virus also circulates as a
quasispecies within a given infected individual. This high vari-
ability represents a challenge for preventive and therapeutic anti-
viral strategies as the virus may rapidly evade the host immune
responses and antivirals [7,8]. The current standard of care
(SOC) of chronic HCV infection consists of pegylated interferon-
a (PegIFN-a) and ribavirin (RBV). Moreover, since 2011, the
new SOC for HCV genotype 1 infected patients is a triple combi-
nation of PegIFN-a/RBV and a HCV protease inhibitor (telaprevir
or boceprevir). Although the addition of these direct-acting antiv-
irals (DAAs) improves outcome, an important limitation of these
DAAs that may contribute to therapy failure is their low genetic
barrier for resistance resulting in drug-escape mutants during
long-term treatment due to their general mechanism of action
[9] and without imposing a large viral ﬁtness cost. DAAs are
not approved for LT [10] and IFN-a-based antiviral therapies have
limited efﬁcacy and tolerability in LT recipients. In addition to
licensed DAAs, other DAAs are at various stages of clinical devel-
opment in combination with PegIFN-a or in IFN-free regimens,
including second-generation protease inhibitors, polymerase
and non-structural protein 5A (NS5A) inhibitors. Although a rapid
decline in HCV RNA levels and/or eradication of HCV in IFN-free
regimens have been demonstrated in clinical trials, viral break-
throughs due to the selection of HCV resistant variants as well
as differences in virological outcomes for different genotypes
and subtypes have been reported. Furthermore, many of these
drugs were associated with side effects and raised issues related
to drug–drug interactions [11]. Finally, it is not yet clear whether
DAA-based therapies will be effective in difﬁcult-to-treat
patients, such as null responders to prior PegIFN-a/RBV therapy,
patients with advanced liver disease, LT recipients, HIV/HCV-
co-infected individuals, hemodialysis patients, or immunosup-
pressed patients [10].
Another challenge in the management of chronically infected
patients is the absence of strategies for prevention of liver graft
infection. Development of preventive strategies based on
anti-HCV envelope antibodies has been challenged by the high
variability of HCV, resulting in rapid viral escape [12–15].
Proof-of-concept of broadly cross-neutralizing antibodies in13 vol. 58 j 375–384
Fig. 1. Host factors required for the hepatitis C virus life cycle as antiviral targets. Outline of the hepatitis C virus (HCV) life cycle in polarized hepatocytes. Host-
targeting agents (HTAs) and biological response modiﬁers (BRMs) are indicated in the ﬁgure according to their presumable point of interference with the viral life cycle. ER,
endoplasmic reticulum; HS, heparan sulfate proteoglycans; RTKs, receptor tyrosine kinases; SR-BI, scavenger receptor BI; CD81, cluster of differentiation 81; CLDN1,
claudin-1; OCLN, occludin; NPC1L1, Niemann-Pick C1-like 1 cholesterol absorption receptor; apo, apolipoprotein; BC, bile canaliculus; TJ, tight junction; Ab, antibody; miR,
microRNA; HMGCoA, 3-hydroxy-3-methyglutaryl CoA reductase; MTP, microsomal triglyceride transfer protein; TLR, Toll-like receptor; IFN, interferon.
Reviewhumans remains to be demonstrated. Thus, there is an unmet
medical need for efﬁcient and safe antiviral strategies for difﬁ-
cult-to-treat patients and for prevention of HCV graft infection
during LT.
Recent proof-of-concept studies in preclinical models and
clinical trials have highlighted that host-targeting agents (HTAs)
provide a novel and promising strategy to address current unmet
medical needs and limitations of SOC. Two main concepts for
HTAs are explored: the ﬁrst strategy aims at interfering with host
factors required for pathogenesis, i.e., to target host factors indis-
pensible for the viral life cycle. These include host cell entry, rep-
lication and assembly factors. The second strategy is to target the
host by boosting the host’s innate immunity, e.g., through the
administration of IFN-k [16] or Toll-like receptor (TLR) agonists
[17–19].
HTAs offer a promising perspective due to the following
features distinguishing them from DAAs: compared to the viral
variability, genetic variability of the host is low. Thus, HTAs
impose a very high genetic barrier to resistance [14,15,20–23].
As HTAs are essential for the viral life cycle, HTAs are character-
ized by a broad pan-genotypic activity while ﬁrst generation
DAAs targeting HCV are characterized by a very narrow antiviral376 Journal of Hepatology 201activity limited to genotype 1. Indeed, HTAs have been shown to
inhibit infection by HCV of all major genotypes, highly variable
quasispecies isolated from individual patients and highly
infectious escape variants that are resistant to host neutralizing
antibodies [14,20,21,24–27]. Finally, by acting through a comple-
mentary mechanism of action, HTAs may synergistically act with
current anti-HCV SOC [28,29]. It is expected that this synergy will
increase the genetic barrier for resistance, shorten treatment
schedules and ameliorate adverse effects by reducing the doses
of the individual compounds.
This review will highlight recent progress in the development
of HTAs targeting HCV infection that have the potential to clear
chronic HCV infection or prevent HCV infection of the liver graft.Host-targeting agents against hepatitis C virus infection
The HCV life cycle may be divided into three main steps: viral
entry into the target cell, viral replication as well as assembly
and release of new infectious virions (Fig. 1). Each step of the
HCV life cycle is dependent on host cell factors [30], thereby
offering numerous targets for HTAs (Figs. 1–3 and Table 1).3 vol. 58 j 375–384
Fig. 2. Host-targeting entry inhibitors for prevention of HCV liver graft infection. During liver transplantation, highly infectious variants of the HCV quasispecies
escaping from the host neutralizing antibodies (nAbs) infect the liver graft. This ‘‘bottleneck’’ effect is related to the implantation of a new graft and the lack of selective
pressure due to the strong immunosuppression (inset). The inset shows the mechanism of re-infection of naïve hepatocytes and viral spread in the liver graft. HCV variants
may spread (i) by cell-free transmission and (ii) by cell–cell transmission. As a consequence, highly infectious HCV variants escaping the host neutralizing immune response
are selected during re-infection of the new liver graft through a ‘‘bottleneck’’ effect [14,15]. HCV entry factors are required for both ways of transmission and are targets of
HTAs. Entry HTAs targeting HCV entry factors inhibit HCV entry and spread of all major genotype as well as of HCV escape variants that re-infect the liver graft
[14,20,21,26,119].
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Viral entry is the ﬁrst step of HCV-host cell interactions and
involves the HCV envelope glycoproteins E1 and E2 as well as
several host factors. It is believed that cell-free HCV entry is a
highly coordinated multistep process (Fig. 1). Highly sulfated
heparan sulfate proteoglycans [31] represent ﬁrst attachment
sites, allowing viral concentration on the basolateral hepatocyte
membrane. The virus then interacts with several entry factors
including scavenger receptor BI (SR-BI) [32], CD81 [33], clau-
din-1 (CLDN1) [34] and occludin (OCLN) [35]. The formation of
CD81-CLDN1 complexes is essential for HCV infection [36,37].
In addition, host cell kinases play an important role in regulating
the HCV entry process [21,38,39]. Among them, two cell surface
receptor tyrosine kinases (RTKs) have been identiﬁed as HCV
entry factors: epidermal growth factor receptor (EGFR) and eph-
rin receptor A2 (EphA2). EGFR and EphA2 promote CD81-CLDN1
co-receptor interaction that is required for HCV entry [21]. The
Niemann-Pick C1-Like1 (NPC1L1) cholesterol absorption receptor
has recently been proposed as another host entry co-factor [40].
Given its physiological role, NPC1L1 may promote HCV entryJournal of Hepatology 201either directly by interacting with the HCV lipoviral particle cho-
lesterol or act as indirect entry factor by modulating cholesterol
homeostasis and membrane composition required for HCV entry.
HCV is internalized via clathrin- and dynamin-dependent endo-
cytosis and is subsequently delivered to the early endosome
[41–44]. CD81 and CLDN1 associate during internalization
[44,45], but it remains unclear whether other HCV host factors
internalize together with HCV. Although required for CD81-
CLDN1 interaction, EGFR does not seem to be essential for
CD81 internalization [44]. The fusion of the viral and the endo-
somal membrane is pH-dependent and involves both viral and
host proteins [41,46–48]. Among host entry factors, CD81 and
CLDN1 play a role in the HCV envelope glycoprotein-dependent
cell–cell fusion process [34,49], which is regulated by RTK func-
tion [21].
An alternative route of viral entry is direct cell–cell transmis-
sion, which also requires numerous host factors including CD81,
SR-BI, CLDN1, OCLN, EGFR, EphA2 and potentially NPC1L1
[21,40,50,51]. As this entry route is resistant to the majority of
neutralizing antibodies described so far, direct cell–cell transmis-
sion probably represents the main process of viral spread [50,51].3 vol. 58 j 375–384 377
Fig. 3. Host-targeting agents exhibit a high genetic barrier of resistance. HCV lipoviral particles circulate as quasispecies of viral variants that infect and replicate in
hepatocytes. The mechanism of viral escape to drug therapy differs between direct-acting antivirals (DAAs) and host targeting agents (HTAs). (Left panel) DAAs efﬁciently
inhibit the replication of DAA-sensitive HCV variants. An HCV variant that is resistant to DAA treatment becomes the predominant HCV variant escaping the antiviral
treatment. (Right panel) Targeting host factors required for HCV entry and infection inhibits a broader spectrum of variants and genotypes since the host factor usage is
usually highly conserved for all viral variants. As a consequence, the genetic barrier of viral resistance to HTAs can be higher compared to many DAAs.
ReviewIt is worth noting that there is an overlap of host factors required
for cell-free and cell–cell transmission, as most of the host factors
involved in cell-free entry have also been described to play a role
in cell–cell transmission.
Targeting HCV entry factors may thus allow preventing initia-
tion of HCV infection, such as after LT, and also reduce viral
spread and thus maintenance of infection. However, while cell-
free HCV entry is strictly dependent on CD81, CD81-independent
routes of cell–cell transmission have been described [52,53]. This
has to be taken into account for the development of HTA directed
against HCV entry factors.
Viral entry has been shown to play an important role in the
pathogenesis of HCV infection, especially during HCV reinfection
of the graft after LT [14,15]. Viral entry is thus a very promising
target for prevention of HCV infection of the liver graft (Fig. 2).
Numerous HTAs directed against host entry factors demonstrated
a potent antiviral activity in vitro (reviewed in [54]). Proof-of-
concept studies of HTAs targeting HCV entry have been con-
ducted in vivo using the chimeric uPA-SCID mouse model. Anti-
bodies directed against CD81 and SR-BI have both been
investigated in prophylactic and post-exposure treatment stud-
ies. Administration of 400 lg of either anti-CD81 or anti-SRBI
monoclonal antibodies (mAbs) completely protected mice from
challenge with HCV [55–57]. Noteworthy, only the administra-
tion of anti-SRBI mAb was able to reduce viral dissemination
[56,57]. The clinically approved EGFR inhibitor erlotinib, prevent-378 Journal of Hepatology 201ing the formation of CLDN1-CD81 complexes, and NPC1L1 inhib-
itor ezetimibe, that decreases systemic cholesterol in patients,
markedly impaired the establishment of HCV infection in the
uPA-SCID mouse model [21,40]. Indeed, administration of erloti-
nib (50 mg/kg/day for 10 days) or ezetimibe (10 mg/kg/day for
2 weeks) prior to viral inoculation signiﬁcantly delayed the kinet-
ics of HCV infection [21,40]. The clinical potential of kinase inhib-
itors has been emphasized in a recent case report describing
rapid virologic response (RVR) after erlotinib monotherapy
(150 mg/day for 12 months) in a HCV-positive HCC patient after
LT and viral recurrence due to a discontinued SOC treatment
[58]. A clinical trial investigating safety and toxicity of erlotinib
in chronically HCV infected patients will soon be conducted to
further assess the potential of kinase inhibitors as anti-HCV drugs
in combination with DAAs. A phase 1b study assessing the safety
of ITX 5061 [26], a small molecule inhibitor targeting the HCV
entry factor SR-BI, in HCV-treatment naive patients, is ongoing
and an open-label, proof-of-concept phase 1b study assessing
the safety and tolerability of ITX 5061 in LT patients has been ini-
tiated (Table 1).
Although HCV entry inhibitors are still at a very early step of
clinical development, it has been demonstrated that combina-
tions of entry inhibitors with IFN-a, DAAs, or other HTAs
in vitro result in an enhanced antiviral activity, compared to
each compound used in monotherapy, in a synergistic manner
[28,29]. This holds promise for entry inhibitors as part of SOC3 vol. 58 j 375–384
Table 1. Host-targeting agents against hepatitis C virus infection.
Step Target Compound with in vivo
proof of concept or
in clinical development
Stage of development Reference
Entry CD81 Anti-CD81 mAbs Mouse model [55]
SR-BI Anti-SR-BI mAbs Mouse model [56, 57]
ITX 5061 Phase 1b ClinicalTrials.gov identifier: 
NCT01165359
EGFR Erlotinib Mouse model [21]
NPC1L1 Ezetimibe Mouse model [40]
Replication miR122 Miravirsen/SPC3649 Phase 2a [23]
HMGCoA reductase Statins Phase 2 [75, 76]
Cyclophilin A SCY-635 Phase 1 [87]
Alisporivir/Debio 025 Phase 3 [91]
Assembly Glucosidase MX-3253 Phase 2 [108]
JOURNAL OF HEPATOLOGYas well as future IFN-sparing regimen(s) for the treatment of
HCV infection.
Key Points 1
• With more than 130 million  chronically infected 
individuals, HCV infection is a major cause of chronic
liver disease and HCC worldwide
• HCV-induced liver cirrhosis and HCC are major
indications for liver transplantation (LT)
• In contrast to hepatitis B virus (HBV), strategies for
immunoprevention of HCV reinfection of the graft are
absent
• The high variability of HCV represents a challenge for
preventive and therapeutic antiviral strategies
• DAAs increase the response to IFN-based antiviral
therapy against HCV genotype 1 but also lead to
selection of drug-resistant HCV variants
• Given their important side effects and drug-drug
interactions, DAAs against HCV are currently not
approved for patients undergoing LT, HCV/HIV 
co-infected patients or pediatric patients
• First generation DAAs are not efficient against all HCV
genotypes
• Although early clinical trials have demonstrated
impressive outcomes for combinations of DAAs in IFN-
free regimens for treatment naïve patients, there will
be a need for novel antivirals addressing resistance,
treatment of patients with co-morbidity, co-medication
or immunosuppression and patients undergoing LTHCV replication inhibitors
Following HCV entry, the HCV RNA genome is released into the
cytosol. Initiation of HCV translation occurs through binding ofJournal of Hepatology 201the 40S ribosomal subunit to the HCV IRES and this association
can be enhanced by miR-122, a liver-speciﬁc microRNA (miRNA)
[59,60]. miR-122 is also an important host factor for HCV repli-
cation [24] and miR-122 sequestration using 122–20OMe oligo-
mers or miR-122 antisense locked nucleic acid SPC3649
reduces HCV replication in a genotype-independent manner
in vitro [24,25]. Interestingly, weekly intravenous administration
of miR-122 antisense locked nucleic acid miravirsen/SPC3649
(5 mg/kg) for 12 weeks to chronically genotype 1 infected chim-
panzees led to sustained suppression of HCV viremia, with no
evidence of viral resistance [61]. Given the physiological role
of miR-122 in cholesterol metabolism, miravirsen/SPC3649 led
to markedly lowered serum cholesterol in animals but no impor-
tant adverse effects were observed [61–63]. Recently, the safety,
tolerability and efﬁcacy of miravirsen/SPC3649 have been
assessed in a phase 2a study (Table 1). Miravirsen/SPC3649
given as a four-week monotherapy (3, 5 and 7 mg/kg) to treat-
ment-naïve genotype 1 patients was well tolerated and provided
robust, dose-dependent antiviral activity that was maintained
for more than four weeks after the end of therapy [23]. Four
out of nine patients treated at the highest dose with miravir-
sen/SPC3649 (7 mg/kg) became HCV RNA undetectable during
the study. Although markedly decreased pretreatment miR-122
levels had been reported in livers of chronic HCV infected
patients who did not achieve virological response during IFN
therapy [64], data from this ﬁrst clinical trial indicate that tar-
geting miR-122 in vivo offers a high barrier to viral resistance
and the potential for combination in a future IFN-free regimen
[23]. Most recently, an allosteric self-cleavable ribozyme capable
of releasing antisense sequence to miR-122 only in the presence
of HCV NS5B was developed in order to minimize potential side
effects related to targeting physiological miR-122 functions [65].
The safety and efﬁcacy of this strategy will next have to be
assessed in vivo.
HCV RNA replication depends on viral protein association
with altered intracellular membranes, probably derived from
the endoplasmic reticulum (ER), in a so called membranous
web (reviewed in [66]). The HCV replication complex, i.e., viral
RNA and viral proteins associated to altered host cell membranes,
is dependent on the host cell lipid metabolism. Indeed, this com-
plex requires elements of cholesterol and fatty acid synthesis and3 vol. 58 j 375–384 379
Review
geranylgeranylation of host proteins, as in vitro HCV replication
can be disrupted by treatment with inhibitors of 3-hydroxy-3-
methyglutaryl CoA (HMGCoA) reductase – such as the statin lov-
astatin, L-659,699 or ZA – or with an inhibitor of protein geranyl-
geranyl transferase I [67,68]. This is in line with data indicating
that HCV replication during acute infection of chimpanzees is
associated with the modulation of several genes involved in lipid
metabolism [69]. Noteworthy, not all HMGCoA reductase inhibi-
tors also inhibit HCV replication as the statin pravastatin exhibits
no anti-HCV activity while ﬂuvastatin has the strongest antiviral
effect [70]. While initial clinical studies indicated that statin
monotherapy did either not signiﬁcantly modulate HCV RNA lev-
els or only modestly reduced HCV RNA in chronic HCV patients
[71–73], statins may represent interesting adjuvants to SOC.
Indeed, ﬂuvastatin (20 mg/day) increased the response to Peg-
IFN-a/RBV, especially in aged women who respond poorly to
SOC [74]. Moreover, in two recent large retrospective analyses,
statin use was associated with an improved sustained virological
response (SVR) in patients receiving combination antiviral ther-
apy [75,76]. However, the addition of ﬂuvastatin (80 mg/day) to
PegIFN-a/RBV did not signiﬁcantly increase SVR rates in HIV/
HCV genotype 1 co-infected patients (also receiving highly active
antiretroviral (HAART) therapy with a complete suppression of
HIV replication) although it did signiﬁcantly improve the RVR
[77]. Taken together, these clinical trials indicate that, with the
exception of HIV/HCV co-infected patients, statins may increase
the efﬁcacy of SOC in chronic HCV infected patients. Interestingly,
most recently small molecule inhibitors of SKI-1/S1P, a lipogenic
pathway regulator upstream of HMGCoA reductase, have been
described [78]. The most potent inhibitor, PF-429242, inhibited
HCVcc replication more efﬁciently than statins and, in contrast
to statins, also reduced infectious particle production [78]. SKI-
1/S1P inhibitors may thus also be considered for development
of novel antivirals.
Cyclophilins are also important host factors for HCV replica-
tion and CypA has been demonstrated to interact with HCV
NS5A [79,80]. Cyclophilins had been identiﬁed as host targets
for antiviral therapy more than 20 years ago as cyclosporine, a
widely used immunosuppressive drug, was demonstrated to
inhibit non-A non-B hepatitis virus [81]. More recently, cyclo-
sporine analogs lacking immunosuppressive activity and dis-
playing higher in vitro antiviral activity, e.g., alisporivir/Debio
025, NIM811 and SCY-635, have been developed [82–84]. These
compounds disrupted CypA-NS5A interaction [85,86]. Moreover,
SCY-635, currently in phase 1 clinical study, enhanced secretion
of type I and type III IFNs in replicon cells and increased the
expression of IFN response genes [87]. These data suggest that
in addition to inhibiting viral replication, CypA inhibitors may
restore the host innate immune responses to HCV inhibitors
and thereby enhance their antiviral activity [87]. Interestingly,
alisporivir/Debio 025 has also proven anti-HIV activity in vitro
as this molecule inhibits CypA-HIV capsid protein binding
[88,89]. CypA inhibitors may thus have an additional beneﬁt in
HIV/HCV co-infected patients. In a phase 1 study, 14-day oral
alipsorivir/Debio 025 (1200 mg twice daily) treatment signiﬁ-
cantly reduced HCV RNA serum levels in HIV/HCV co-infected
patients independently of the HCV genotype (1, 3 and 4) [90].
However, a potent synergy between alisporivir/Debio 025 (200,
600 and 1200 mg twice a day for one week and then once daily)380 Journal of Hepatology 201and PegIFN-a was also observed in a subsequent phase 2 study
demonstrating that addition of alisporivir/Debio 025 increased
RVR [91]. Further phase 2 trials also demonstrated improved
efﬁcacy and good tolerance adding alisporivir/Debio 025 to
PegIFN-a/RBV without selection of resistant variants (reviewed
in [92]). This CypA inhibitor is thus characterized by a high bar-
rier to resistance and is the ﬁrst HTA that reached phase 3 stud-
ies (Table 1). Given three cases of acute pancreatitis, the FDA
recently put a clinical hold on this trial before proceeding to
the next steps. The fact that the combination of alisporivir/Debio
025 with DAAs resulted in additive antiviral activity in short-
term in vitro antiviral assays [93] holds promise for HTAs as part
of future IFN-sparing regimen(s) for the treatment of HCV
infection.HCV assembly/release inhibitors
Following HCV replication, new infectious virions are assembled
in the vicinity of lipid droplets and ER [94–97]. The HCV particle
is composed of an encapsidated RNA genome that is surrounded
by an envelope composed of the envelope glycoproteins E1 and
E2 [98,99]. E1 and E2 associate as a non-covalent heterodimer
and are essential for viral infectivity as they mediate interactions
with different host cell factors during viral binding and entry. E1
and E2 are heavily N-glycosylated, contain ER retention signals
and are processed within the ER by glucosidases I and II to ensure
proper folding and assembly [98]. HCV assembly has been sug-
gested to parallel VLDL assembly [100–102]. Microsomal triglyc-
eride transfer protein (MTP), the rate limiting enzyme of VLDL
assembly [103], probably also contributes to HCV particle assem-
bly [101].
Targeting host glucosidases thus represents a promising
strategy to interfere with viral infectivity (Table 1). MX-3253/
celgosivir (reviewed in [104]), an alpha-glucosidase I inhibitor,
induces misfolding of HCV envelope glycoproteins and leads to
reduced viral infectivity in vitro [105,106]. MX-3253/celgosivir
demonstrated modest antiviral efﬁcacy in a phase 2a mono-
therapy study (200 and 400 mg/day for 12 weeks) in treat-
ment-naive and IFN-intolerant genotype 1 HCV patients [107].
While MX-3253/celgosivir (400 mg/day for 12 weeks) demon-
strated clinical beneﬁt in combination with PegIFN-a/RBV in
chronic HCV genotype 1 infected patients [108], the further
development of MX-3253/celgosivir for HCV infection has subse-
quently been halted.
Compounds inhibiting VLDL assembly, such as MTP inhibitors,
also reduce HCV release from infected cells [100–102]. MTP
inhibitors have been developed for treatment of dyslipidemia
and currently several MTP inhibitors are in clinical trials for the
treatment of hypercholesterolemia or hyperlipidemia (reviewed
in [109]). However, whether MTP inhibitors display an antiviral
effect against HCV infection in vivo remains to be determined.
Moreover, recent screens revealed that several approved drugs
display antiviral activity against HCV by targeting HCV assembly
and/or release: these studies identiﬁed two anti-cancer drugs,
pterostilbene (a methylated form of resveratrol) and torimefene
(a derivative of tamoxifene) [110] as well as quinidine, a class I
antiarrhythmic agent [111] as potential antivirals against HCV.
Taken together, these data indicate the further potential of clini-3 vol. 58 j 375–384
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cal development of HCV assembly inhibitors for the treatment of
chronic hepatitis C.
Clinical perspectives of HTAs interfering with the HCV life cycle
To date, the main issue of anti-HCV SOC is to avoid viral resis-
tance and severe side effects. Generally speaking, the use of DAAs
against different potential highly variable viruses, such as HCV,
HIV or inﬂuenza virus, is associated with the development of
resistance, while HTAs, acting on cellular targets that are less
prone to mutations, may impose a higher genetic barrier for
resistance (Fig. 3) [112,113]. On the other hand, the principle the-
oretical drawback of using HTAs is their potential greater cellular
toxicity. Nevertheless, it has to be pointed out that the develop-
ment of several DAAs targeting HCV, such as BILN 2061, had to
be stopped due to severe side effects [114]. Moreover, the major-
ity of current drugs widely used for cardiovascular, neurological
or endocrine diseases as well as cancer, target host proteins
[115–117]. Thus, side effects have to be carefully evaluated for
novel antiviral strategies against hepatitis C irrespective of the
drug target.
While DAAs allow increasing the virological response of HCV
genotype 1 infected patients, a large fraction of chronic HCV
patients, especially HIV/HCV co-infected patients and patients
undergoing LT, will not be eligible for DAAs given the important
drug–drug interactions with anti-retroviral therapy and immu-
nosuppressive agents. Noteworthy, synergy between IFN-a, DAAs
and HTAs allowing to decrease the concentrations of the individ-
ual compounds [28,29] holds promise for a variety of possibilities
of future combination therapy treatments of hepatitis C infection
that may be adapted to the individual patient. Furthermore, given
(i) the importance of host entry factors for HCV reinfection of the
graft during LT [15], (ii) the broad antiviral activity of entry inhib-
itors against viral escape variants selected during LT [14,20,21],
and (iii) the synergy between entry inhibitors and neutralizing
anti-HCV envelope antibodies [27], entry inhibitors also repre-
sent a promising strategy to prevent viral reinfection of the liver
graft (Fig. 2).Conclusions and perspectives
The goal of current anti-HCV SOC is sustained viral eradication.
However, due to the high variability of HCV, viral resistance
and subsequent treatment failure remain major challenges.
Moreover, therapeutic strategies for a large fraction of patients,
especially HIV/HCV co-infected patients, patients with immuno-
suppression and co-morbidity and patients undergoing LT remain
limited [7,118]. Although early clinical trials have demonstrated
impressive outcomes for combinations of DAAs in IFN-free regi-
mens for treatment naïve patients [11] there will be a need for
antivirals addressing resistance, treatment of patients with co-
morbidity, co-medication or immunosuppression and patients
undergoing LT [10].
Alternative or complementary approaches to current
anti-HCV therapies are to boost the host’s innate immunity or
interfere with host factors required for pathogenesis. HTAs act
on cellular targets and thus may impose a higher genetic barrier
for resistance than DAAs. Moreover, HTAs are usually character-
ized by a pan-genotypic antiviral activity. In the past years,Journal of Hepatology 201tremendous progress has been made in the characterization of
the HCV life cycle
Key Points 2
• The HCV life cycle offers several well characterized
host targets for antiviral therapy
• Due to low genetic variability of host factors, HTAs
may impose a higher genetic barrier to resistance than
DAAs
• Most HTAs have a pan-genotypic antiviral activity
• Given their complementary mechanism of action, HTAs
may inhibit viral infection in a synergistic manner in
combination with IFN-α and/or DAAs
• As for DAAs, host-related adverse effects need to be
carefully addressed
• Pan-genotypic antivirals alisporivir/Debio 025, a
specific HTA targeting cyclophilin A, and miravirsen/
SPC3649, a miR-122 antisense locked nucleic acid,
have completed proof-of-concept in humans
• Many other HTAs targeting the HCV life cycle are at
different stages of development
• Synergy between IFN-α, DAAs and HTAs holds
promise for a variety of possible combination therapies
for prevention and treatment of hepatitis C 
• HTAs offer the perspective to improve antiviral
treatment by decreasing resistance, shortening of
treatment duration and ameliorating adverse effects
• Given the importance of host entry factors for HCV
reinfection of the graft during LT, entry inhibitors 
represent a promising strategy to prevent viral 
reinfection of the liver graft
and several host targets for speciﬁc antiviral therapy have been
uncovered. Alisporivir/Debio 025 and miravirsen/SPC3649, two
HTAs inhibiting HCV replication, recently completed proof-of-con-
cept in humans [23,92]. Many other HTAs targeting the HCV life cy-
cle are at different stages of preclinical and clinical development
suggesting that the therapeutic arsenal against chronic HCV infec-
tion may widen within the next years. Furthermore, recent studies
underscored the importance of host factors during HCV liver graft
infection and highlighted the potential of HCV entry inhibitors for
prevention of graft infection during LT [15,20,21,57,119].
The recent preclinical and clinical development of HTAs for
HCV as well as novel HTA-based strategies for other pathogens
including other viruses and bacteria [120] highlights the promise
of this approach to address unmet medical needs in the preven-
tion and treatment of virus-induced liver disease.
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